Abstract
Immunotherapy has become a prominent approach for the treatment of cancer. Targeted killing of malignant cells by adoptive transfer of chimeric antigen receptor (CAR) T cells is a promising immunotherapy technique in oncology. However, the identification of cell surface antigens unique to tumor cells against which CAR T cells can be engineered has historically been challenging and not well documented in solid tumors. Here, we describe a generalized method to construct a cell subtype-specific surface antigen profile (i.e., surfaceome) from cell lines and identify high-confidence antigens as effective targets for CAR T cell therapy by integrating transcriptomics and cell surface proteomics. This method is widely applicable to all therapies utilizing CAR T cells, such as cancer, as well as infectious and autoimmune diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chaplin DD (2006) 1. Overview of the human immune response. J Allergy Clin Immunol 117(2 Suppl Mini-Primer):S430–S435. https://doi.org/10.1016/j.jaci.2005.09.034
Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3(4):388–398. https://doi.org/10.1158/2159-8290.CD-12-0548
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273
Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12(1):3–13. https://doi.org/10.1006/scbi.2001.0404
Hale M, Mesojednik T, Romano Ibarra GS, Sahni J, Bernard A, Sommer K, Scharenberg AM, Rawlings DJ, Wagner TA (2017) Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol Ther 25(3):570–579. https://doi.org/10.1016/j.ymthe.2016.12.023
Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D (1998) HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391(6665):397–401. https://doi.org/10.1038/34929
Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG (2012) Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother 61(7):953–962. https://doi.org/10.1007/s00262-012-1254-0
Fesnak AD, June CH, Levine BL (2016) Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16(9):566–581. https://doi.org/10.1038/nrc.2016.97
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3:16011. https://doi.org/10.1038/mto.2016.11
Vogel C, Marcotte EM (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13(4):227–232. https://doi.org/10.1038/nrg3185
Lee JK, Bangayan NJ, Chai T, Smith BA, Pariva TE, Yun S, Vashisht A, Zhang Q, Park JW, Corey E, Huang J, Graeber TG, Wohlschlegel J, Witte ON (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115(19):E4473–E4482. https://doi.org/10.1073/pnas.1802354115
Bausch-Fluck D, Hofmann A, Bock T, Frei AP, Cerciello F, Jacobs A, Moest H, Omasits U, Gundry RL, Yoon C, Schiess R, Schmidt A, Mirkowska P, Hartlova A, Van Eyk JE, Bourquin JP, Aebersold R, Boheler KR, Zandstra P, Wollscheid B (2015) A mass spectrometric-derived cell surface protein atlas. PLoS One 10(3):e0121314. https://doi.org/10.1371/journal.pone.0121314
Plaisier SB, Taschereau R, Wong JA, Graeber TG (2010) Rank-rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures. Nucleic Acids Res 38(17):e169. https://doi.org/10.1093/nar/gkq636
Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD, Musselman-Brown A, Schmidt H, Amstutz P, Craft B, Goldman M, Rosenbloom K, Cline M, O’Connor B, Hanna M, Birger C, Kent WJ, Patterson DA, Joseph AD, Zhu J, Zaranek S, Getz G, Haussler D, Paten B (2017) Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol 35(4):314–316. https://doi.org/10.1038/nbt.3772
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https://doi.org/10.1186/s13059-014-0550-8
Acknowledgments
We thank the UCLA Technology Center for Genomics & Bioinformatics and the UCLA Proteomics Research Center for providing assistance with the workflows. This work was supported by the Department of Defense Prostate Cancer Research Program Physician Research Award (W81XWH-17-1-0129) and a Prostate Cancer Young Investigator Award to J.K.L.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
DeLucia, D.C., Lee, J.K. (2020). Identification of Cell Surface Targets for CAR T Cell Immunotherapy. In: Katz, S., Rabinovich, P. (eds) Cell Reprogramming for Immunotherapy. Methods in Molecular Biology, vol 2097. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0203-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0203-4_2
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0202-7
Online ISBN: 978-1-0716-0203-4
eBook Packages: Springer Protocols